Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

MR-Guided Ultrasound Ablation: Safer and Better Treatment for Prostate Cancer

MR-Guided Ultrasound Ablation: Safer and Better Treatment for Prostate Cancer

Prostate cancer may be treated more effectively with therapeutic ultrasound while avoiding standard treatment adverse effects. A study presented on 2 December 2019 reported treatment of prostatic both benign and malignant enlargement using MR (magnetic resonance) -guided focused ultrasound ablation. Prostate cancer, with lung cancer, is among the 2 most common male cancers worldwide. The small gland below the bladder is anatomically close to the rectum, urethra, penis passing through it, and nerves, making standard interventions difficult. Most rely on surgery or radiation, which may fail or cause serious incontinence, impotence, and bowel problems. Radiofrequency or laser ablation or cryotherapy and other less popular techniques have not been widely adopted because they require advanced image guidance and temperature monitoring.

how prostate cancer ablation with tusla works

The diagram shows controlled, precise prostate tumor ablation using TULSA (transurethral ultrasound ablation).

MR -Guided Ultrasound

A newer method with major therapeutic potential is MR -guided transurethral ablation, commercially called TULSA. It is minimally invasive, directing precisely calculated ultrasound doses into abnormal prostate tissue while limiting healthy tissue damage. High-intensity focused ultrasound heating cancer cells until destroyed is currently the least invasive method of physically removing cancerous tissue from this gland. MR images are combined with ultrasound images to guide the beam precisely. It can currently treat early disease not spreading beyond the prostate, before or after other treatments, for example failed radiation.

The Study

Researchers analyzed multicenter 12-month outcomes in the TULSA ablation clinical trial (TACT= Tusla Ablation Clicin Trial). Data came from men with median age 65, totaling 115. All had low- or intermediate-risk, gland-confined early prostate cancer. Whole-gland TULSA treatment averaged 51 minutes.

Findings

After treatment, % 80 had no detectable cancer with clinically significant size or behavior, radiological and clinical complete response. In % 65, one-year review biopsies found no cancer. Blood prostate-specific antigen (PSA) fell % 95. Adverse effects were minimal, with no bowel complications. MR -guided TULSA results appear impressive. Prostate volume decreased more than % 90, with impotence in very few and almost no incontinence. This offers major advantages over conventional ultrasound. It can be outpatient/day treatment with same-day discharge. TULSA may be repeated if necessary, and surgery or radiation remain possible. TULSA is approved in Europe and the USA under FDA 510 (k). Further studies must confirm early results; if confirmed, it could greatly improve benign prostatic hyperplasia and prostate cancer treatment.

Sources

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

MR-Guided Ultrasound Ablation: Safer and Better Treatment for Prostate Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy